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Abstract
Caveolae are non-clathrin invaginations of the plasma membrane in most cell types; they are involved in signalling functions and molecule traf-
ficking, thus modulating several biological functions, including cell growth, apoptosis and angiogenesis. The major structural protein in caveolae
is caveolin-1, which is known to act as a key regulator in cancer onset and progression through its role as a tumour suppressor. Caveolin-1 can
also promote cell proliferation, survival and metastasis as well as chemo- and radioresistance. Here, we discuss recent findings and novel con-
cepts that support a role for caveolin-1 in cancer development and its distant spreading. We also address the potential application of caveolin-1
in tumour therapy and diagnosis.
Keywords: caveolin-1 cancermetastases biomarkers targeted therapy
Introduction
Caveolae (from the Latin word for ‘little cavities’) are 50–100 nm
non-clathrin, flask-shaped invaginations of the plasma membrane that
function as specialized membrane microdomains. Caveolae regulate
signal transduction within the cell, as well as numerous other cellular
processes including vesicular transport (transcytosis, endocytosis),
cholesterol homeostasis, cell migration and the cell cycle [1]. Three
small coat proteins have been identified in caveolae. Specifically,
caveolin-1 (Cav1) and caveolin-2 (Cav2) are widely coexpressed in
fully differentiated mesenchymal and endothelial normal tissues as
well as in many solid tumours, whereas caveolin-3 (Cav3) is primarily
expressed in muscle cells [2–4].
Caveolae represent one of the multiple raft endocytic pathways,
not a major route of endocytosis, and act as an alternative to clathrin-
coated pits. They contain several signalling molecules, such as
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G-proteins, non-receptor tyrosine kinases and endothelial nitric oxide
synthase (eNOS) and function as organizing centres that concentrate
key signalling transducers. Beside, caveolae seem to be directly
involved in the cell response to mechanical stress: specifically, it has
been reported that primary cell response to an acute mechanical
stress occurs through the rapid flattening of caveolae into the plasma
membrane [5]. It has been proposed that the complex relationship
that links caveolae, caveolin and transmembrane signalling can be
explained by the ‘caveolae signalling hypothesis’, in which the com-
partmentalization of signalling molecules within caveolae could allow
for the efficient and rapid coupling of activated receptors to more than
one effector system [6].
Recently, polymerase I and transcript release factor (PFTR; also
known as Cav-p60 or Cavin), a soluble cytosolic protein, has been
found to be required for caveolae formation [7]. PFTR-cavin is
recruited to plasma domains containing phosphatidylserine (PS), cho-
lesterol and oligomerized caveolins [7]. By binding these domains
PFTR-cavin stabilizes the membrane curvature to produce the classic
flask shape of caveolae. It indeed associates with mature caveolae at
the plasma membrane but not with non-caveolar caveolin (in the
Golgi complex or in mutant forms of caveolin) [7]. Interestingly,
knockdown of PFTR-cavin reduces caveolae density and PFTR-cavin
loss releases caveolar components, including caveolins, into the
plasma membrane. Related proteins such as serum-deprivation pro-
tein response (SDPR)-cavin-2 and sdr-related gene product that
binds to c-kinase (SRBC)-cavin-3 have also been reported to regulate
membrane tubulation and caveola endocytosis: moreover, membrane
remodelling and interdependent polarization of Cav1 and PTRF/cavin-
1 in migrating cells has been recently shown to regulate cell migration
[8–10].
Cav1 is an integral membrane 178-amino acid protein of 21–
22 kD that was first identified in 1953. In 1992 Rothberg et al. named
the protein caveolin and identified it as a unique array of filaments or
strands that form striated coatings decorating the cytoplasmic sur-
faces of caveolae [11]. The Cav1 human gene is located on chromo-
some 7 in region q31.1 at the D7S522 locus [12]. The protein is
synthesized in the endoplasmic reticulum (ER) and assembled along
the membranes of the secretory pathway into large caveolar domains
that subsequently travel towards the plasma membrane: recycling
pathway for caveolae and caveolin is not yet clear. In vivo, two iso-
forms of Cav1 are known to exist: a-caveolin that contains the resi-
dues from 1 to 178 and b-caveolin that contains the residues from 32
to 178. Cav1 exerts its function by directly interacting with partner
proteins through a defined, highly conserved region (aa 82-101)
called the ‘caveolin-scaffolding domain’ (CSD) [3]. In this view, Cav1
could play a role of intracellular signalling modulator. Isoform a of
the protein can be phosphorylated by Src on its tyrosine residue 14
[13, 14]. It is degraded through an ubiquitination process, and
‘caveosomes’ are late endosomal compartments that are modified by
the accumulation of overexpressed Cav1 and awaiting degradation
[15]. Recently, phospho-Cav1 has been reported to be a mechano-
transducer that acts via PKC to relieve Egr1 transcriptional inhibition
of Cav1 and cavin-1, thus defining a novel feedback regulatory loop to
caveolae biogenesis [16].
The ability of Cav1 to modulate intracellular signalling has impor-
tant implications in numerous human biological and pathological con-
ditions, including tumourigenesis. In fact, during the past 20 years,
several studies have carefully investigated the role of Cav1 in cancer
initiation and progression, proving that this multifunctional protein
regulates many cancer-associated processes, such as cell transfor-
mation, tumour growth, cell migration, invasion, multidrug resistance
and angiogenesis. Despite this extensive body of work, our knowl-
edge regarding the relationship between Cav1 function and tumouri-
genesis remains incomplete. The role of Cav1 in tumour onset and
progression has been previously covered by several reports. The
present review aims to highlight and discuss the most recent data
which unveil the varied roles played by Cav1 during tumourigenesis,
as growing evidence suggests that it may act both as inhibitor and
promoter of growth signalling. Due to its versatile functions, the pro-
tein is now being exploited as a promising target for both cancer ther-
apeutic and diagnostic approaches.
WHEN: Cav1 expression and disease
stage
In early studies, Cav1 expression was reported to be down-regulated
in a wide range of human tumours and cell lines, which hinted at its
tumour suppressor abilities [17–19]. In those settings Cav1 appears
to be downregulated and seems to play a negative role in cancer
transformation (Table 1). Many oncogenes, such as SRC, RAS, BCR-
ABL, transcriptionally down-regulate Cav1 expression. Cerezo et al.
have recently shown that Cav1-deficient fibroblasts show a faster
escape from quiescence and progression through the cell cycle [20].
This effect is consistent with the potential role of Cav1 as a tumour
suppressor. Cav1-negative cells features tumourigenic properties,
such as the anchorage independent growth capacity, suggesting that
loss of Cav1 regulation is an important step in the acquisition of the
transformed phenotype.
Supporting its role as a tumour suppressor gene, a sporadic dom-
inant negative Cav1 mutation has been described in the literature.
Hayashi et al. first reported a somatic punctiform Cav1 mutation at
codon 132 (the P132L change that converts proline-132 into leucine)
in 16% of the cases of primary human breast cancers that were
examined [21, 22]. In contrast, in vivo experiments showed that Met-
1 cells (a mouse luminal mammary epithelial cell line) harbouring
Cav1-1P132L formed tumours that were larger than Met-1 cells with
wild-type Cav1 and had a greater metastatic potential [23]. Bonuccelli
et al. has suggested that in primary tumour formation, Cav1-1P132L
acts as a loss-of-function mutation, whereas in the metastatic pro-
cess, it behaves as a gain-of-function mutation promoting cell migra-
tion and invasion [24]. In fact, several signalling pathways (e.g. EGF,
HGF and TGF-b) that are implicated in cell migration, invasion and
metastasis appear to be up-regulated by Cav1-1P132L. Notably,
structural analysis of other point mutations at position 132 of Cav1
(P132A, P132I, P132V, P132G, P132W, P132F) indicates that proline
132 is critical in supporting proper Cav1 behaviour [25]. However, it
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should also be noted that the existence of the P132L mutation has
recently been questioned [26].
Although Cav1 is likely to behave as a tumour suppressor protein
in early phases of tumour onset, growing evidence suggests that
more advanced or metastatic tumours have Cav1 activation (Table 1).
In fact, Cav1 is commonly up-regulated in several advanced epithelial
tumours including prostate, kidney, breast and bladder carcinomas
and brain tumours [27–37]. In melanoma cell lines, Felicetti et al.
have recently highlighted the tumour-promoting functional role of
Cav1, demonstrating that high expression of phospho-Cav1 positively
correlated with increased anchorage independence, invasion and
migration [38]. Supporting these data, unpublished data from our
group demonstrate increased Cav1 expression in metastatic
compared with non-metastatic melanoma cell lines (Fig. 1). In
Table 1 Caveolin-1 expression in primary carcinoma and in metastatic disease and correlation with in vivo and in vitro effects.
Clinicopathological correlations
References
In vitro effects In vivo effects
Cav1 in primary cancer
Cav1 tumour suppression
Sarcoma bone and
soft tissues
Increase anchorage independence,
invasion and migration
Increase in the metastatic potential [17]
GIST Reduced expression (IHC), but no correlation with
expression status and cell mitosis and tumour grade
[18]
Ovarian cancer Suppression of tumour cell survival [19]
Cav1 tumour promotion
Prostate cancer Gleason score, positive margins, aggressive cancer
recurrence, lymph nodes involvement
[28, 35, 36]
RCC Poor disease-free survival; higher mRNA Cav1 increase
tumour stage; tumour size, TNM stage and grade
[29, 40]
Bladder carcinoma Aggressiveness, tumour grade and stage [30]
Brain tumour Oligodendroglioma: Shorter survival
Ependymomas: Unfavourable patient outcome
[31–33]
Breast carcinoma Shorter disease-free and overall survival [27]
NSCLC Advanced pathological TNM stage and shorter survival [37, 43, 45]
Cav1 up-regulation associated with metastatic disease
RCC Correlation with microvessel
density, metastasis and poor prognosis
[40]
ESCC Lymph node metastasis and worse prognosis [41]
NSCLC Induction of filopodia formation Lymph node metastasis [42, 43]
SCLC Increase in the metastatic potential [44]
Hepatocellular carcinoma Promotion of cell proliferation,
migration and invasion
Increase in the metastatic potential [48, 49]
Malignant melanoma Increase anchorage independence,
invasion and migration
[38]
Ewing’s sarcoma Increased migration and invasion of the
extracellular matrix
Increase in the metastatic potential [47]
Cav1: caveolin-1; GIST: gastrointestinal stromal tumour; IHC: immunohistochemistry; RCC: renal cell carcinoma; ESCC: oesophageal squamous
cell carcinoma; NSCLC: non-small cells lung carcinoma; SCLC: small cells lung carcinoma.
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addition, Sunaga et al. demonstrated that Cav1 expression was
down-regulated in 95% of small cell lung cancer cell lines, which dis-
played Cav1 gene promoter hypermethylation. In contrast, Cav1
expression was maintained in 76% of non-small cell lung cancer
(NSCLC) cell lines [39].
Up-regulation of Cav1 in some primary tumour cells has been
reported to be associated with metastatic disease progression [40–
48]. Sainz-Jaspeado et al. proposed that Cav1 overexpression con-
tributes to Ewing’s sarcoma tumour cell migration, invasion of the
extracellular matrix and metastasis [47]. In hepatocellular carcinoma,
Cav1 up-regulation seems to promote cell proliferation, migration and
invasion in vitro and metastatic potential in vivo.[48]. Similarly, ele-
vated levels of Cav1 increased cell motility and invasion in the human
hepatocellular carcinoma cell lines (HepG2 and Huh7), and caveolae
disruption reduced SNU-449 and SNU-47 cell motility and invasion
[49]. In lung adenocarcinoma cell lines, the enhanced metastatic
potential associated with Cav1 up-regulation depends on the induc-
tion of filopodia formation [42].
The contribution of Cav1 to cancer progression appears to be
complex and remains controversial. In an attempt to resolve the con-
flicts between the biological and functional data, it has been sug-
gested that in the early stages of cancer progression Cav1 restrains
tumour growth, whereas in the advanced stages of disease, Cav1 has
a pro-survival and tumour promoting role [50]. According to this
view, Cav1 could play a role as either a tumour suppressor gene or an
oncogene, and the switch is likely governed by tumour stage and
tumour temporal context [51].
HOW: Cav1 may promote tumour
spreading
Cancer is a multistep genetic and epigenetic disease that results from
the progressive accumulation of mutations which either inactivate
tumour suppressor genes or activate dominant proto-oncogenes
[52]. These aberrant events free cells from proliferative control and
allow primary tumour formation. The initial tumour growth is followed
by metastatic spread, and ultimately, metastases that are resistant
to conventional therapies represent the major cause of death from
cancer.
As discussed above, the role played by Cav1 in cancer and pro-
gression has not been fully clarified. Although lacking a fundamental
mechanistic understanding to explain a fully Cav1-induced malignant
phenotype, it is well documented that Cav1 cooperates with other
proteins to promote cancer dissemination by affecting critical func-
tions of cellular maintenance and homeostasis. During the early
stages of tumour progression, Cav1 negatively controls cell-cycle
progression and restrains cell proliferation, whereas growing evi-
dence suggests that Cav1 may induce more advanced cancer phases
[3]. Cav1 interacts with a series of molecules/receptors which do not
specifically function in caveolae, but which regulate initial steps of
cells transformation as well as their metastatic potential [3, 53]. It
should be noted that not all the data reported below have been inde-
pendently repeated in multiple model systems, therefore not all have
the same significance.
Cav1 and cell-cycle modulation
Cyclin D1 belongs to a family of proteins that promotes cancer cell
progression through the G1-S phase of the cell cycle by binding the
cyclin-dependent kinase CDK4. This interaction ultimately induces
phosphorylation of the retinoblastoma protein pRb, with release of
the E2F transcription factor allowing cells to progress in the cell cycle
[54]. This phenomenon been identified in several epithelial tumours,
including breast, colon, ovarian, prostate and lung tumours. Impor-
tantly for human metastatic lung adenocarcinoma and small cell lung
cancer (SCLC), it has been reported that cyclin D1 expression is regu-
lated by Cav1 expression and aberrant activation of the signal trans-
ducer and activator of transcription-3 (STAT3) [55]. Cav1 silencing
induces the stable arrest of proliferation in metastatic lung cancer cell
lines through a significant decrease in both cyclin D1 expression and
phosphorylated AKT expression, as well as a decrease in its down-
stream transducers phosphorylated ERK and STAT3 [49]. STAT3 is
an oncoprotein that is frequently hyper-activated by phosphorylation
of a conserved tyrosine residue in response to extracellular signalling
molecules such as cytokines and growth factors [56]. Conversely, it
has been demonstrated that STAT3 can regulate the expression and
function of Cav1 by directly binding the Cav1 promoter and inhibiting
its transcription [57]. These findings reveal a reciprocal network
between Cav1 and STAT3 that regulates distant cancer metastasis.
Forkhead box M1 (FoxM1) is a transcription factor that plays a role as
regulator of cell-cycle phases (G1/S and G2/M), angiogenesis,
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Fig. 1 Effects of caveolin-1 activation that promote cancer progression.
The left side of the figure shows the Western blot analysis of caveolin-1
expression in a metastatic (WM 266-4) compared with a non-metastatic
melanoma cell line (A375; A). On the right of the figure, one case of a
primary poorly differentiated lung carcinoma (B: TC scan; D: E&E, 409;
E: Cav1, 409) and its corresponding brain metastasis (C: TC scan; F:
E&E, 409; G: Cav1, 409) are reported. The primary lung lesion showed
a focal and faint cytoplasmic and membrane Cav1 staining (D and E),
whereas in the brain metastasis, (F and G) Cav1 expression was diffuse
and intense.
328 ª 2013 The Authors
Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
invasion and metastasis [58]. Recently, a direct correlation between
Cav1 and FoxM1 expression has been reported in pancreatic cancer
cells [59]. High Cav1 expression correlated with poor tumour differ-
entiation, advanced tumour stage and distant metastasis. In addition,
Cav1 and FoxM1 expression directly correlated, and FoxM1 positively
transactivated Cav1 activity by binding to the promoter region.
Cav1 and growth factors signalling
Another mechanism by which Cav1 may affect cell fate is by its ability
to interact with growth factors and cytokines. With respect to growth
factors, many previous studies have linked Cav1 to the epidermal
growth factor (EGF) and EGF receptor (EGFR) pair. Although Cav1
seems to down- regulate signal transduction, its phosphorylated form
has been associated with EGF-induced cell migration and anoikis [3,
60]. On the other hand, EGF induces tyrosine phosphorylation of
Cav1, which, in turn, is essential for EGFR transactivation and AKT
signalling [61]. Cav1 can also interact with the insulin growth factor
receptor (IGFR) by its ability to bind cholesterol, and receptor regula-
tion has been linked to the insulin-induced tyrosine phosphorylation
of Cav1. Cav1 phosphorylation leads to the caveolar recruitment of
several SH2 residue containing proteins, such as Grb7, that are
responsible for IGFR activation [62, 63].
Cav1 and Rho-GTPases
Rho-GTPases are members of the RAS superfamily of small guano-
sine triphosphatases (GTP-ases) that participate in the regulation of
cell movement and migration by controlling actin-myosin filament
assembly to form stress fibres and maintain focal adhesion [64]. Rho
induces the binding of Cav1 to actin cross-linking protein filamin A,
which produces an alignment between structures that are positive for
Cav1/filamin and stress fibres. This suggests that Cav1 plays a role at
the interface of the cytoskeleton [65]. Cav1 could regulate cell polari-
zation and directional migration through a process involving Src and
Rho-GTPases [66].
Cav1 and integrins
Integrins physiologically regulate cell adhesion by binding to extracel-
lular proteins. Cav1 is a protein that physically represents a link and
functions as an adaptor between integrins and tyrosine kinase signal-
ling [67, 68]. Tyrosine phosphorylated Cav1 (pY14Cav1), which is vir-
tually extracaveolar, is associated with Rho activation and Src-
dependent regulation of tumour cell motility, stabilization of focal
adhesion kinases (FAK) within focal adhesions (FAs) and enhance-
ment of tumour cell migration and invasion [69]. Recently, Arpaia
et al. demonstrated that the interaction between Cav1 and Rho-GTP-
ases promotes metastasis by stimulating the expression of a5-inte-
grin [70]. Beside, Cav1 phosphorylated on tyrosine 14 contributes to
adhesion maturation and tumour cell migration through a crosstalk
with galectin-3 [71]. Indeed galectin-3 binding to Mgat5-modified N-
glycans functions together with pY14Cav1 to stabilize FAK within FAs,
and thereby promotes FA disassembly and turnover.
Recently, it has been demonstrated in glioblastoma that Cav1 con-
trols a5b1 integrin expression by the TGFb/TGFbRI/Smad2 pathway
[72]. Cav1 acts as a negative regulator of a5b1 integrin expression in
glioma cells and specifically, loss of Cav1 confers a more aggressive
phenotype [73]. In addition, Cav1 depletion can block the association
between Src kinases and ß1 integrin, resulting in both the loss of
focal adhesion domains that mediate the interaction between the ECM
and cytoskeletal proteins and increased tumour migration [74].
Recently, Cav1 has been reported to reduce metastatic potential in
melanoma cells through the suppression of the Integrin/Src/FAK sig-
nalling pathway [75].
Cav1, matrix remodelling and cell–cell adhesion
The metastatic potential of malignant cells relies on their invasion and
migration abilities in response to changes in the extracellular matrix
surrounding the tumour. Physiologically, Cav1 controls cell motility
by interfering with the cytoskeleton and modulating cell interaction
with the extracellular matrix [76]. In fact, Cav1 regulates matrix deg-
radation and interacts with several molecules involved in cell motility
and dynamics [3].
Caveolin-1 participates in the remodelling of the extracellular
matrix (ECM) by promoting interactions with matrix metalloproteinas-
es (MMPs). MMPs are a family of zinc-containing proteolytic
enzymes that play a critical role in tumour invasion and metastasis by
favouring the degradation of different extracellular matrix proteins
[77]. Among all MMPs, MMP9 and MMP2 (gelatinase A and B) are
reported to be frequently overexpressed in cancer progression and
positively associated with metastases [78]. Although Cav1 has been
shown to decrease MMP2 and MMP9 activity, Cav1 can be up-regu-
lated during Epithelial-Mesenchymal Transition (EMT) by acting on
other members of the MMP family [79–81]. For example, Cav1 over-
expression, in association with the secretion of MMP3 and MMP11,
enhances nasopharyngeal carcinoma cell migration [82]. Moreover,
Cav1 may affect cancer cell adhesion by modulating E-cadherin (E-
cad), which is a major component of adherens junctions [83]. Cadh-
erin-mediated adhesion plays a crucial role in maintaining cell–cell
contacts and reducing metastatic disease. The binding of b-catenin to
membrane E-cad is a prerequisite for cell adhesion because the cyto-
plasmic domain of E-cad binds b-catenin, and the resulting complex
is linked through a-catenin to the cytoskeleton [84, 85]. Loss of E-
cad is a prerequisite for migratory activity and development of an
invasive metastatic phenotype in cancer [86]. Cav1 and E-cad co-
localize and interact at the cell surface. The connection between the
two molecules may differ according to the different cell types where
they are expressed. Some reports documented a Cav1 mediated
increase in cell–cell adhesion, in association with the stabilization of
adherens junctions and E-cad expression [87, 88]. Interestingly, in
lymph node metastases from head and neck squamous cell carcino-
mas (HNSCCs), Cav1 overexpression has been associated with the
abnormal expression of at least one member of the E-cad/a-b cate-
nins complex, as well as multiple ErbB receptors [89].
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Cav1 and invadopodia formation
Invadopodia are ventral membrane protrusions that can degrade the
extracellular matrix, mainly through membrane type 1 matrix metallo-
proteinase (MT1-MMP) activity [90]. Their role is important during
metastatic and invasive processes. Cav1 seems to be able to regulate
invadopodia-mediated extracellular matrix degradation [91]. In fact,
Cav1 accumulates at invadopodia and both co-localize and co-traffic
with MT1-MMP. Cells with reduced Cav1 expression showed a signifi-
cant decrease in invadopodia formation and gelatin degradation
activity [83, 84].
Cav1 and angiogenesis
To obtain the blood supply necessary for their growth and overcome
ensuing local hypoxia and metabolic needs, tumour cells can tilt the
balance towards stimulatory angiogenic factors and drive vascular
growth. Neovasculature generated by tumour cells is typically tortu-
ous and permeable, features that favour intravasation, a very early
event in the metastatic process that is represented by entrance of
tumour cells into the bloodstream. Neoangiogenesis is a multifaceted
process governed by several factors. Among them, vascular endothe-
lial growth factor (VEGF) regulates angiogenesis by the complex inter-
action of cellular-signalling pathways. VEGF secreted by tumour cells
activates endothelial cells (ECs) in a paracrine manner and sets in
motion all of the functions that are required for angiogenesis, includ-
ing matrix degradation, migration, proliferation and the sprouting of
new vessels from the existing ones. VEGF-induced angiogenesis and
hyperpermeability require nitric oxide (NO) that is produced by the
activity of nitric oxide synthase (eNOS), a NOS isoform known to be
concentrated in caveolae in endothelial cells [92]. Cav1 is able to
interact with eNOS by inducing inhibition of NO synthesis. Moreover,
reactive oxygen species (ROS) are now widely recognized to contrib-
ute to both cell homeostasis and cancer, and NO contributes to oxida-
tive stress [93]. eNOS is the main source of vascular NO, and
aberrant regulation of eNOS activity is linked to a range of vascular
diseases and to the pro-angiogenic activity that characterizes many
solid tumours. Cav1 acts as an inhibitory clamp that maintains eNOS
in an inactive state until haemodynamic forces that are transmitted
into the caveolae, uncouple eNOS from caveolin for activation. Thus,
the inhibitory effect of Cav1 on eNOS may have an impact on vascular
permeability and angiogenesis.
The relationship between the tumour angiogenesis promoted by
Cav1 and the enhanced metastatic potential of a neoplastic clone has
yet to be elucidated. Cav1-deficient mice show a constitutive eNOS
activation which results in increased microvascular permeability:
down-regulation of Cav1 is predicted to promote uncontrolled eNOS
activity, thereby facilitating tumour onset and stimulating tumour vas-
culature by inducing the expression of angiogenic growth factors that
regulate endothelial cell growth and tubule formation [94, 95]. In mul-
tiple myeloma, VEGF secreted by neoplastic cells is able to induce a
paracrine Src-mediated Cav1 phosphorylation [96]. In hepatocarcino-
ma (HCC), overexpression of Cav1 has been associated with the over-
expression of VEGF and the increase in microvessel density in
unpaired arteries. Thus, angiogenesis may be affected by Cav1, and
through this mechanism it facilitates metastatic dissemination in HCC
[97].
WHERE: stromal Cav1 and
microenvironment
Tumours are made up of a mixed population of cells that includes
normal structures adjacent to transformed clones, and both interact
with the microenvironment. Mechanical forces driving these interac-
tions cooperate in tumour invasion and metastasis, and cancer-asso-
ciated fibroblasts can biomechanically remodel the extracellular
matrix surrounding the tumour. Recently, several authors have
focused their attention on Cav1 expression in the tumour stromal
cells (stromal Cav1) rather than Cav1 cellular expression, as evidence
suggests that there may be an important role for stromal Cav1 in pro-
moting tumour progression and metastasis. Goetz et al. reported that
stromal Cav1 is a regulator of matrix-dependent cell behaviour, high-
lighting its ability to facilitate invasion and metastatic potential
through a regulation of Rho activity and p190 localization and phos-
phorylation [98]. Consistent with these data, the expression of Cav1
in carcinoma-associated fibroblasts facilitates in vitro directional
migration and invasiveness. However, this finding appears to contrast
previous reports that propose that the absence of stromal Cav1 is a
negative prognostic factor in cancer [99]. The absence of stromal
Cav1 has been reported to predict early tumour recurrence and lymph
node metastases and to be a predictor of poor clinical outcome in
breast cancer [100]. In addition, loss of stromal Cav1 was associated
with the disease progression of invasive breast cancer in ductal carci-
noma in situ [101]. Similarly, high stromal Cav1 levels have been
demonstrated to correlate with reduced metastasis and improved sur-
vival [102]. Recently, high Cav1 cell expression, in association with
an absence of Cav1 stromal expression, has been reported to be clo-
sely associated with poor outcome in a subset of breast cancer
patients [103]. A deficiency of stromal Cav1 in human prostate cancer
has been identified as a biomarker for tumour progression to meta-
static disease as well [104]. Reduced stromal Cav1 expression has
also been reported to label a subgroup of patients that have an unfa-
vourable survival prognosis and aggressive malignant melanoma
metastases [105]. Sotgia et al. have recently demonstrated that
Cav1/ fibroblasts secrete high levels of pro-angiogenic or pro-
tumourigenic factors, such as VEGF, platelet-derived growth factor,
MET, interleukins and chemokines, which have been shown to sup-
port metastatic disease [106]. This mechanism could partially explain
why the loss of stromal Cav1 in cancer-associated fibroblasts corre-
lates with metastatic dissemination. In addition, a loss of stromal
Cav1 has been reported to lead to the overexpression of plasminogen
inhibitor type 1 and 2 (PAI-1 and PAI-2), likely as a consequence of
increased oxidative stress. Cancer cells activate transcription factors
in adjacent stroma via oxidative stress (Warburg effect), which repre-
sents a crucial step for cancer progression and dissemination. Stro-
mal cells lacking Cav1 undergo aerobic glycolysis and secrete
energy-rich metabolites that directly feed cancer cells and fuel
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mitochondrial respiration of adjacent cells through the phenomenon
called the ‘reverse Warburg effect’ [107].
To date, the discordant role of stromal Cav1 on tumour progres-
sion and metastasis appears to be poorly understood although sev-
eral mechanisms have been proposed by different authors to explain
its critical function as a regulator of tumour-surrounding tissue
remodelling and desmoplastic processes [98, 108].
Cav1 knockout mice models
Truly caveolae-deficient mice have been generated and contributed to
assess Cav1 functions in vivo in the context of a whole animal. More-
over, a knockout mouse phenotype is often different from a drug
inhibitor phenotype as the latter is usually partial. Notably, loss of a
major cellular organelle imparts no developmental abnormality or
lethality.
Interestingly, Cav1 (/) null mice completely lack caveolae,
while ectopic expression of Cav1 is sufficient to induce caveolae in
cells that were previously lacking these organelles [109]. Knockout
animals displayed severe dysfunction of the vascular system. Surpris-
ingly, the deletion of these organelles was not lethal, a pronounced
thickening of lung alveolar septa caused by an uncontrolled fibrosis.
Cav1/ mice demonstrate organ-specific growth-related disorders in
stromal cells that normally have high levels of Cav1 expression [110].
In many of these organs, epithelial cell growth/differentiation abnor-
malities were also observed, yet in most of these sites the epithelial
cells normally express low to non-detectable levels of Cav1. This
observation suggests that loss of Cav1 function in stromal cells of
various organs directly leads to a disorganized stromal compartment
that, in turn, indirectly promotes abnormal growth and differentiation
of adjacent epithelium.
Caveolin-1-deficient mice feature some interesting pathophysio-
logical changes, with clearly abnormal lungs featuring airway hyper-
reactivity and a hypotonic vasculature [111]. Park et al. reported that
double-knockout Cav1 and Cav3 mice are viable and fertile, although
they lack morphologically identifiable caveolae in endothelia, adipo-
cytes, smooth muscle cells, skeletal muscle fibres and cardiac myo-
cytes [112]. Authors also show that those mice are deficient in all
three caveolin gene products, as Cav2 is unstable in the absence of
Cav1. Interestingly, dual ablation of both Cav1 and Cav3 genes in
mice leads to a pleiotropic defect in caveolae formation and severe
cardiomyopathy with interstitial/perivascular fibrosis. Thus, Cav1/
mice are markedly abnormal, although Cav1 is not expressed in
cardiac myocytes. However, Cav1 is abundantly expressed in the
non-myocytic cells of the heart, such as cardiac fibroblasts and endo-
thelia. In addition, endothelial and iNOS levels are dramatically
up-regulated [113]. Besides Cav1/ mice may have problems with
lipid metabolism and/or adipocyte functioning [114]. Although serum
insulin, glucose and cholesterol levels are entirely normal, Cav1 null
mice have severely elevated triglyceride and free fatty acid levels,
especially in the post-prandial state. This is consistent with previously
shown functions of Cav1 in lipid metabolism and homeostasis [115].
In addition, although Cav1 plays a role in several oncogenic pathways,
Cav1 null mice do not present a higher incidence of carcinomas.
Coherently,—as Cav1 does not directly play as oncogene or full
tumour suppressor molecule—they do not show signs of hyperprolif-
eration. Very recently, it has been shown that genetic ablation of Cav1
differentially affects melanoma tumour growth and metastasis in
mice, as Cav1-deficient dermal fibroblasts are able to promote the
growth of melanoma cells via enhanced paracrine cytokine signalling
[116]. In contrast the ability of melanoma cells to form lung metasta-
ses seems to be significantly reduced in Cav1KO mice: this behaviour
has been linked to the inability of melanoma cells to adhere to and to
transmigrate through a monolayer of endothelial cells lacking Cav1.
WHY: to hunt Cav1 in cancer and
metastasis
As discussed above, Cav1 plays a key role in cell signalling and in
tumour progression towards the metastatic stage. Several strategies
are now under investigation to target Cav1 for the prevention of
tumour progression and dissemination: all of them attempt to exploit
the unique properties of Cav1 in molecular trafficking, and include tar-
geting Cav1 using antisense and siRNA approaches, re-expressing
ectopic caveolin, introducing a CSD and lowering cholesterol with sta-
tins or other drugs. Targeting vascular endothelium is a relatively
novel approach to tumour therapy, and the selective endocytosis
mediated by Cav1 represents one of the most promising current strat-
egies to achieve localized gene expression and direct damage of
endothelial cells. Indeed, caveolae provide a unique vascular pathway
for both selective uptake of molecules and their delivery to specific
cells and tissues. Targeted gene delivery of Cav1 has been undertaken
using a different approach to alter Cav1 expression in vascular endo-
thelial cells. A recently developed cell-permeable peptide, derived
from the amino acids of the CSD of Cav1 and termed cavtratin, has
been shown to reduce microvascular hyperpermeability and to delay
tumour progression in mice by inhibiting eNOS [117]. Moreover, cav-
tratin inhibits the phosphorylation of the NGF receptor TrkA as well as
the activity of downstream components of the NGF signalling pathway
in oligodendrogliomas [118]. The cell-permeable peptide is likely not
a true drug candidate but a tool. In this perspective, the CSD of cave-
olin may also be considered as a novel therapeutic target. On the
other hand, caveolae can be utilized as a useful transport pathway to
improve tissue-directed drug and gene delivery. This is an interesting
approach, particularly if one considers that caveolins affect sensitivity
to chemotherapy. In addition, caveolae provide a novel vehicle to deli-
ver imaging agents and nanoparticles to specific tissues in vivo.
Higher Cav1 expression in advanced tumours is exploited by the
recently developed nanoparticle albumin-bound (nab) technology,
which promises to have broad utility in cancer therapy and proposes
a mechanism to deliver nab-driven chemotherapy that exploits the
cargo properties of Cav1.
The nano-shuttle system is believed to activate an albumin-spe-
cific (Gp60) receptor-mediated transcytosis pathway in the neoplastic
cell by using Cav1-activated caveolar transport [119]. In addition to
caveolae and caveolins, targeted agents could be used as promising
tools for imaging to identify the primary tumour and metastatic
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lesions and to localize metastatic lesions and vascular patterns of
neoplastic embolization.
Interaction with chemo agents and radiations
The Cav1 role in radio- and chemoresistance of tumour cells also pro-
vides rationale for targeting Cav1 in cancer. The phenomenon of phar-
maco- and radioresistance is still a major open issue in cancer
treatment that has prompted studies to clarify the mechanisms of
drug action and anti-neoplastic resistance (Fig. 1). Cellular levels of
Cav1 have been shown to be increased in multidrug resistant cancer
cells [120]. Cav1 knockdown sensitizes human renal carcinoma cells
to doxorubicin-induced apoptosis and reduces lung metastasis in a
mouse model [121]. Exposure to taxol, a molecule that stabilizes
microtubules, may affect the cycling of Cav1 between the plasma
membrane and the Golgi apparatus [122]. Taxol induces Cav1 up-reg-
ulation in A549 cells in an independent manner from the expression
of P-glycoprotein [123]. Cav1 up-regulation following exposure to
taxol may represent a way for the cell to compensate for the effect of
the drug on the microtubule cytoskeleton. A connection between
Cav1 and the DNA repair process has been demonstrated, given that
silencing of Cav1 increased the levels of residual DNA double-strand
breaks in irradiated 3D cell cultures, and Cav1 knockdown sensitized
pancreatic tumour cell lines grown in 3D lrECM to X-rays [124]. Cav1
expression has also been shown to be significantly associated with
poor prognosis and drug resistance in advanced non-small cell lung
cancer patients after treatment with gemcitabine [125]. Interestingly,
Dittmann et al. showed that Src kinase activation following irradiation
triggers Cav1-dependent EGFR internalization into caveolae [126].
Therefore, EGFR is able to reach the nucleus and bind to DNA-depen-
dent protein kinase (PK), which is an essential mechanism of non-
homologous end-joining DNA repair. Treatment with cetuximab,
which binds to the extracellular domain of EGFR, results in receptor
internalization and formation of an intracellular complex of EGFR,
Cav1 and the monoclonal antibody. Radiation-induced activation and
nuclear translocation of EGFR are mediated through Src kinase activ-
ity in a Cav1-dependent process. A different mechanism through
which Cav1 is involved in the response to ionizing radiation is related
to the interaction of Cav1 with focal adhesion proteins. This process
has demonstrated that Cav1-silenced pancreatic cancer cells seem to
be sensitized to ionizing radiation, and this suggests that Cav1 acts as
pro-survival factor in the cellular response to ionizing radiation [127].
In addition, enhanced radiosensitivity of Cav1-deficient mice has been
associated with increased apoptosis and abnormal proliferation of
intestinal crypt stem cells of the small intestine, resulting in increased
susceptibility to c-radiation [128].
The recent discovery of Cav1 as a metastasis promoter has
challenged its role as biomarker of tumour progression. As dis-
cussed above, the up-regulation of intracellular Cav1 is associated
with the activation of several pro-survival and pro-invasive path-
ways. Nevertheless, there is a growing interest in secreted Cav1 as
a biologically active molecule that promotes cell survival and angio-
genesis within the tumour microenvironment. Secreted Cav1 can
be reproducibly detected in peripheral blood by using specific
assays. The ultimate goal of such an approach is to allow patient
stratification into metastasis-specific risk categories based on Cav1
levels.
Exosomes: Cav1 as a new tumour marker?
Exosomes are 30–100 nm small membrane vesicles containing cyto-
solic and membrane proteins that are released through an exocytosis
pathway by most cell types [129]. Their release appears to be finely
modulated under both physiological and pathological conditions. Exo-
some release has been found to be dramatically increased in cancer
[130]. Thus, exosomes have been proposed to play an important pro-
tumourigenic role, facilitating both tumour progression and metasta-
sis by modifying the host microenvironment. In recent years, exo-
some release by neoplastic cells in biological body fluids, such as
blood and urine, has been extensively investigated. Cav1 has been
reported to be involved in prostasome (vesicular organelles secreted
by prostate epithelial cells) secretion in the human prostate cancer
cell line PC-3 [131]. More recently, Logozzi et al. have demonstrated
a strong expression of Cav1 in exosomes secreted by human mela-
noma cells in vitro and in those obtained from plasma of SCID mice
engrafted with melanoma tumours: on the contrary, it is undetectable
in cellular extracts and in exosomes from normal human cells such
as primary monocyte-derived macrophages [132]. Authors observed
that a significant increase in exosomes expressing tumour markers
such as Cav1 can be observed in the plasma of melanoma patients
with respect to healthy individuals. As a consequence, Cav1
plasma levels could bear relevance as a possible prognostic mar-
ker in melanoma patients, and exosomes may represent a hallmark
of more aggressive melanoma that identifies patients with poor
outcome. Besides authors findings suggest that an exosome-
specific ELISA assay may be used to detect and quantify circulat-
ing exosomes in melanoma patients [132]. However, further
investigations are still necessary to understand the role of Cav1 in
exosome biology.
Concluding remarks
Caveolin-1, a principal structural component of caveolar membrane
domains, contributes to cancer development, but its precise role in
cancer regulation remains unclear. Growing evidence supports the
hypothesis that Cav1 is switched on during neoplastic progression,
and its overexpression characterizes the most advanced stages of
several malignant diseases. Cav1 acts as cargo molecule and orches-
trates the trafficking across the cell plasma membrane, which is
required for metastasis. Importantly, Cav1 plays a dual regulatory role
in controlling microvascular permeability: (i) as a structural protein
that is required for caveolae formation and caveolar transcytosis and
(ii) as a tonic inhibitor of eNOS activity to negatively regulate the para-
cellular pathway. Finally, Cav1 expression can mediate chemo- and
radioresistance of tumour cells. Overall Cav1 is a promising target for
selective cancer diagnosis and therapy as modulator of intracellular
signalling. In particular, Cav1 targeting could promote the penetration
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of anticancer drugs, gene vectors or imaging probes through the
endothelial cell barrier.
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